0      0

VD09 - What’s Circulating? The Future of Cancer Detection and Treatment

‐ Nov 11, 2023 4:45pm


Adria Myers has no relevant financial relationships to disclose.
Holly Chitwood has participated in oncology nurse education advisory boards with Gilead Sciences, Astra Zeneca, and in biomarker database peer review for the Oncology Nursing Society.

Learning Objectives:

  • Define circulating tumor DNA (ctDNA) and appraise evolving technology
  • Describe current ctDNA application with solid tumors and emerging indications in practice with an overview of commercially available assays
  • Discuss the advanced practice provider's role in ctDNA utilization
  • Identify emerging clinical trial data and evolving recommendations for ctDNA utilization


You must be logged in and own this session in order to post comments.